Trial Profile

Phase 1b study of CDX-0159 in chronic inducible urticaria

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Barzolvolimab (Primary)
Indications Urticaria
Focus Adverse reactions
Sponsors Celldex Therapeutics Inc

Most Recent Events

29 Mar 2021 According to a Celldex Therapeutics media release, the company expects to initiate this study in third quarter of 2021.
16 Oct 2020 New trial record
13 Oct 2020 According to a Celldex Therapeutics media release, the company expects to initiate this study in coming weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com